Ilmarinen, Pinja
Juboori, Hind
Tuomisto, Leena E.
Niemelä, Onni
Sintonen, Harri
Kankaanranta, Hannu
Funding for this research was provided by:
Tampereen Tuberkuloosisäätiö
Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö
the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (VTR, Tampere, Finland), the Medical Research Fund of Seinäjoki Central Hospital
Article History
Received: 18 May 2019
Accepted: 16 October 2019
First Online: 6 November 2019
Competing interests
: Dr. Sintonen is the developer of the 15D and obtains royalties from its electronic versions. Outside the submitted work, Dr. Ilmarinen reports grants and personal fees from Astra Zeneca, personal fees from Mundipharma, personal fees from GlaxoSmithKline, personal fees from Orion, personal fees from Novartis. Dr. Kankaanranta reports grants, personal fees and non-financial support from AstraZeneca, personal fees from Chiesi Pharma AB, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Novartis, personal fees from Mundipharma, personal fees and non-financial support from Orion Pharma, personal fees from SanofiGenzyme, personal fees from GlaxoSmithKline, outside the submitted work. Dr. Tuomisto reports non-financial support from Chiesi, non-financial support from Boehringer-Ingelheim, personal fees from Astra Zeneca, non-financial support from Orion Pharma, non-financial support from TEVA, other from Novartis, outside the submitted work. Dr. Niemelä and Dr. Juboori declare no potential conflict of interest.